Last quarter, Bristol-Myers Squibb walked back its 2017 guidance in a move some industry-watchers attributed to immuno-oncology star Opdivo and its recent setbacks. Analysts' recommendations show a 12-month target price of …
Drive
[at Wall St. Cheat Sheet] – Bristol-Myers has a 42 percent positive surprise history, having topped the whisper in 11 of …
Bristol-Myers Squibb‘s (NYSE:BMY) stock has inched up a little following its Q1 2017 earnings release last week, as the company reported better than expected results. Its key cancer drug Opdivo grew nearly 60% despite competitive …
Bristol-Myers Squibb
Frankly, I'm amazed at how far Bristol-Myers Squibb (BMY) has fallen over the last two months. This diversified, mega-cap pharmaceutical has lost about a quarter of its value since Aug. 1. That's a lot of market cap. The reason for this loss …
Territory
One stock that might be an intriguing choice for investors right now is Bristol-Myers Squibb Company BMY. This is because this security in the Large Cap Pharmaceutical space is seeing solid earnings estimate revision activity, and is …
Bristol-Myers Squibb Company presently has an average rating of “Hold” and an average price target of $61.90. Get Bristol-Myers Squibb Company alerts: This story was originally posted by Chaffey Breeze ... 2017/02/27/bristol-myers
Breeze2mon
Jefferies cut its price target on BMY stock to $65. Nevertheless, the shares are up 0.2% at $53.50, and have pared their year-to-date deficit to 8.5%. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), …
Bristol-Myers Squibb
Additional country approvals for this indication total more than 50. At the close of trading session on Friday, May 19, …
Bristol-Myers Squibb